Scientia Vascular CEO Rick Randall discusses the company, its novel technology and plans for growth in an interview with SmartTRAK. 

Scientia Vascular CEO Rick Randall discusses the company’s recent leadership transition, his priorities and vision as CEO and what’s next for the company in a recent interview with SmartTRAK.

Click on the following video (36:39 min) to learn more about the company, its differentiated microfabrication technology, product portfolio, marketing strategies and growth plans. Interview topics by timecode are provided below, as is a link to download a complete transcript of the interview.

 

Interview Outline by Timecode:

00:06 Introduction to Scientia Vascular, CEO Rick Randall, the leadership transition and his priorities as CEO.
05:08 Innovative products, new technologies, market positioning and differentiating Scientia in a crowded market.
09:54 Leveraging microfabrication technology and expanding the product portfolio.
14:18 Future directions in neurovascular and peripheral vascular. Clinical research and product validation.
22:07 Company growth and market strategy. Leading products and revenue mix.
26:59 Market share and business evolution.
29:26 Financing strategies and future investments.
31:57 Long-term growth strategies and potential IPO.

Click the button below to download and read the complete transcript of SmartTRAK's interview with Scientia Vascular CEO Rick Randall conducted by Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies.

Perfuze CEO Wayne Allen discusses the company, its novel technology and how the company plans to capture share in the US Market for Mechanical Thrombectomy Devices in an interview with SmartTRAK. 

To see the full interview, click on the following video (32:35 min). An outline of the interview by timecode and a link to download a transcript of the interview are provided below.

Interview Topics by Timecode: 

00:07 Perfuze CEO Wayne Allen discusses his background, the company and its mission.
03:26 Overview of Perfuze technology and products.
07:05 Regulatory approvals and clinical research
08:43 Status of MARRS IDE Study and future plans. Seeking a standalone thrombectomy indication.
11:08 Differentiating Millipede 088 Catheter and competing in the market.
15:40 Status of Millipede 088’s limited market release in the US, commercial strategy, and obtaining real-world insights.
19:29 Funding and timeline to finance and accelerate commercial expansion, clinical, R&D initiatives and pipeline.
21:18 Long-term goals, future innovations/indications and growth.
24:47 Strategic vision, capturing share and market positioning.
27:13 Addressing uncertainties, supply chain challenges, tariffs and future outlook.
28:46 What’s next for Perfuze and closing remarks.

 

Click the button below to download the complete transcript of our interview with Perfuze CEO Wayne Allen, in which he discusses his company, its novel technology and strategies for growth in the US Market for Mechanical Thrombectomy. Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies, conducted the interview.

Dr. Marc Russo discusses his research on ultra-low frequency SCS and its potential to treat nociceptive back pain in an interview with SmartTRAK at NANS 2025. 

While spinal cord stimulation (SCS) has been a standard treatment for chronic neuropathic pain conditions for over 40 years, SCS technologies to date have not demonstrated efficacy in the treatment of chronic low back pain that is predominantly nociceptive in origin. At the recent North American Neuromodulation Society (NANS) 2025 Annual Meeting in Orlando, Dr. Marc Russo, a professor at the University of Newcastle in Australia, presented data evaluating the use of ultra-low frequency (ULF) SCS (Presidio Medical) for the treatment of nociceptive chronic low back pain, which affects a much larger segment of the population than those affected by chronic neuropathic pain.

While chronic low back pain can have a mix of both nociceptive and neuropathic pain, a technology that can effectively treat nociceptive pain, or even both types of pain, could be a game changer. In an interview with SmartTRAK, Dr. Russo discusses ULF SCS, its mechanism of action and how this research is charting new territory in the treatment of chronic low back pain.

To find out more about ULF SCS and Dr. Russo’s latest research, listen to the interview below (12:59 min). A link to download a complete transcript of the interview is also provided below. 

SmartTRAK: Anne Staylor here with SmartTRAK. Today, I'm at the North American Neuromodulation Society Annual Meeting and I have the opportunity to speak with Dr. Marc Russo, a professor at the University of Newcastle in Australia. 

Hi, Dr. Russo. So nice to see you again.

Dr. Marc Russo: Hi, Anne. Likewise.

I always like to talk to you about innovation. You seem to be on the leading edge of these things all the time. So here at the meeting, you've presented on a new technology that you've been studying, ultra-low frequency spinal cord stimulation. You presented a study. Let's start by having you provide an overview about what ultra-low frequency is for spinal cord stimulation and then we'll get into the study. Can you start with that?

Dr. Marc Russo: Yes. Absolutely. And I think we really have to set the scene by talking about the original research work that looked at how we could actually interact with nervous system tissue. So that work goes all the way back to the work of Huxley back in 1961. And in that, they showed  ... (read more)

Click the button below to download the full transcript of the interview "NANS 2025: Charting New Territory With Ultra-Low Frequency Spinal Cord Stimulation."  In this conversation, Dr. Mark Russo, past president of the International Neuromodulation Society and associate professor at the University of Newcastle, NSW, Australia, discusses his research on ultra-low frequency SCS and its potential to treat nociceptive back pain with Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies.

SmartTRAK reports on the latest research and innovation in neurointervention from ESMINT 2024. 

The European Society for Minimally Invasive Neurological Therapy (ESMINT) Annual Congress is unique, not only because it addresses issues and trends pertinent to Europe, but because it also provides a worldwide perspective that features cutting edge science, industry symposia, a novel “startup alley” and the latest advancements in therapies and techniques affecting the market for the minimally invasive treatment of ischemic and hemorrhagic stroke.

In this downloadable article, SmartTRAK highlights the top news, research and advances in neurointervention from ESMINT 2024 held September 4-6 in Marseille, France. This includes:

• Innovation in Access Devices
  • Over the last several years, companies have been developing new catheters and access devices designed to better navigate difficult anatomy and tortuous vessels to reach target vessels and achieve rapid access during neurovascular intervention. With this in mind, two companies have developed novel guidewires with remotely shapeable tips that can be used to address different types of anatomy and facilitate successful catheterization ... (read more)
• Advances in Mechanical Thrombectomy from the Following Companies
  • Rapid Medical
  • Q’Apel Medical
  • Balt
  • WallabyPhenox
  • Acandis 
  • Stryker
  • Medtronic
  • PenumbraPenumbra
  • JNJ MedTech
  • Terumo Neuro
  • Vesalio
• Current and Emerging Flow Diverters
  • Since the FDA approved Medtronic’s Pipeline Embolization Device in 2011, flow diversion has revolutionized the treatment of intracranial aneurysms and allowed clinicians to treat a wider range of aneurysms in more complex anatomies. Today, flow diverters continue to evolve and almost every manufacturer of neurovascular devices currently has or is developing a flow diverter as part of its hemorrhagic stroke portfolio. (read more)
    
    

Click the button below to download and read the comprehensive "ESMINT 2024: What's New in Neurointervention" Market Outlook article by Anne Staylor, SmartTRAK Executive Editor VP and GM, Neuro Therapies.

In this article,  SmartTRAK  highlights the latest research and innovation in interventional pain management from the American Society of Pain & Neuroscience (ASPN) Annual Conference, held July 11-14  in Miami, FL. The ASPN meeting has grown exponentially over the last several years and is a reflection of the growing interest in providing more treatment options to patients with chronic intractable pain. (See also  SmartTRAK’s  interview with ASPN Chairman Tim Deer, MD,  ASPN 2024: Evolving Ideas into Innovation and Practice .)

 

Among the many topics covered in detail in this informative article are:

 

Spinal Cord Stimulation

• Correlating Neurophysiological Data to Pain and Treatment Success
• FAST US Real-World Data
• Remote SCS Management
• Data Supporting Expanded Indications
  • Nonsurgical Back Pain
  • Painful Diabetic Neuropathy
  • Nociceptive Pain

Peripheral Nerve Stimulation

• Craniofacial, Head/Neck Pain
• Comfort PNS Devices
• Next Generation PNS Devices
  

Minimally Invasive Spine

• Basivertebral Nerve Ablation (BVNA)
• Minimally Invasive SI Joint Fusion
• Lumbar Decompression for Lumbar Spinal Stenosis
  

Regenerative and Restorative Medicine

• Intradiscal Therapy

Click the button below to download and read the complete "ASPN 2024: Research and Innovation in Interventional Pain" Market Outlook article by Anne Staylor, SmartTRAK Executive Editor, VP & GM of Neuro Therapies.